Oncology Exam Domains 2026: Complete Guide to All 17 Content Areas

How the AOBIM Oncology Blueprint Is Built

This guide covers the subspecialty Certification in Oncology offered by the American Osteopathic Board of Internal Medicine (AOBIM), with certification approval through the American Osteopathic Association (AOA). It is not the ABIM Medical Oncology exam and it is not a combined hematology-oncology examination. That distinction matters the moment you open a blueprint, because the content areas, their ordering, and their weighting are specific to AOBIM's published outline.

The blueprint divides the exam into 17 content areas. Instead of publishing a single fixed weight for each, AOBIM publishes a percentage range. A domain listed at 5-9% might account for roughly the lower or upper end of that band on any given exam form. Treat the ranges as planning guides, not promises. Do not collapse them into midpoints in your head; a range tells you how much flexibility the exam writers have, and the smart response is to be comfortable across the whole band.

If you are new to the credential itself, our overview pages on what Oncology certification is and the eligibility requirements and how to qualify explain who sits for this exam. This article focuses on what happens once you are in the testing room: which content areas dominate and how to think about each one.

Exam Format, Scoring and Fees

The initial written examination contains 300 multiple-choice questions delivered over seven hours. That is a long sitting, and domain familiarity matters partly because it saves time. When you recognize a presentation quickly, you bank minutes for the harder integrative items later in the day.

Passing requires a scaled score of at least 500 on the AOA 200-800 scale. Importantly, 500 is not a raw percentage of correct answers. Scaled scoring adjusts for the difficulty of the particular exam form, so you cannot convert "I need X% right" into a reliable target. For a deeper treatment, see our page on the Oncology passing score.

Budget accordingly: the $800 initial fee becomes $1,040 if you pay the late surcharge, which is a avoidable $240 cost for missing a deadline. The score audit is optional and must be requested within one month of results. For the full financial picture, including costs beyond the exam itself, read our Oncology certification cost breakdown. Eligibility includes AOA board certification in internal medicine, two years of an ACGME-accredited or AOA-recognized Oncology or Hematology/Oncology fellowship, an active medical license, ethical standing, and a completed application with program-director verification.

All 17 Content Areas at a Glance

The table below lists every domain with its official range, in blueprint order. Use it as your master reference when building a plan.

Notice how the weighting shapes strategy. The top two domains by range, hematologic malignancies and genitourinary tumors, are both substantial. But the next tier is crowded: gastrointestinal tumors, chemotherapy toxicity, breast tumors, and supportive care all sit in overlapping bands. Breadth across the middle of the blueprint is what separates a comfortable pass from a stressful one.

The Heavy-Hitting Domains

Hematologic Malignancies (15-19%)

Because this domain can reach nearly one-fifth of the exam, weakness here is expensive. Candidates coming from a solid-tumor-heavy fellowship experience should plan extra time for it. Remember that the exam also tests complications that bleed into other domains, such as tumor lysis, infections in neutropenic patients, and treatment toxicities.

Genitourinary Tumors (10-14%)

Genitourinary disease is one of the more treatment-landscape-dependent areas, so read primary guideline logic rather than memorizing isolated drug names. Questions often reward understanding why a regimen fits a clinical scenario.

Solid Tumor Domains: What to Master

Beyond genitourinary disease, the blueprint devotes several domains to organ-specific cancers. Together they form the backbone of clinical oncology knowledge.

Gastrointestinal Tumors (6-10%)

Colorectal, gastric, esophageal, and related cancers. Expect staging-driven treatment decisions, adjuvant versus palliative intent, and biomarker-guided therapy selection. Know the role of molecular testing in directing systemic options.

Breast Tumors (5-9%)

Hormone receptor and HER2 status structure nearly every management decision. Be fluent in adjuvant endocrine therapy considerations, targeted agents, and the logic of neoadjuvant treatment. Hereditary risk and genetic counseling intersect here with the cancer genetics content in Domain 1.

Thoracic Tumors (4-8%)

Lung cancer dominates: histology, molecular drivers, and the shift toward biomarker-directed and immunotherapy-based strategies. Staging and combined-modality approaches for locally advanced disease are recurring themes.

Gynecologic Tumors (3-7%)

Ovarian, endometrial, and cervical cancers. Understand staging, surgical-systemic treatment relationships, and how hereditary syndromes influence both risk and therapy.

Pancreatic and Liver Cancer (2-6%)

A compact domain with high clinical stakes. Focus on resectability concepts, the role of systemic therapy, and liver cancer risk factors and surveillance in at-risk populations.

Skin Cancer, Head and Neck, and Sarcoma (each 1-5%)

These smaller domains still contribute meaningfully when summed. Skin cancer covers melanoma and non-melanoma entities; head and neck cancer emphasizes combined-modality treatment and organ preservation concepts; bone, soft tissue, and sarcoma questions test histology-driven management of an uncommon but conceptually distinct group of tumors.

Toxicity, Supportive Care and Paraneoplastic Domains

Several domains are not organ-based at all, and candidates who study only by tumor type often underprepare for them. Taken together, they carry real weight.

Chemotherapy toxicity (6-10%) overlaps with gastrointestinal tumors in range, which means a toxicity-focused study block can pay off as much as a tumor-focused one. These questions are frequently scenario-based: a patient on a named regimen presents with a symptom, and you must identify the cause and the next step.

Small Domains Worth Their Points

Four domains carry narrower ranges but should not be skipped, because they are often the most efficient to learn.

• Pharmacology/cancer biology/cancer genetics (2-6%): mechanisms of drug classes, tumor biology fundamentals, and hereditary cancer syndromes. This content supports every tumor domain.
• Prevention/screening (2-6%): evidence-based screening approaches, risk-reduction strategies, and high-risk surveillance.
• Opportunistic infection (1-4%): infections in neutropenic, transplant, and immunosuppressed patients, including prophylaxis principles.
• Cancer trials (1-3%): trial design, endpoints, and interpretation of results. It is the smallest range on the blueprint, but the concepts are learnable in a short, focused session.

AOBIM Versus ABIM: Do Not Mix the Blueprints

Many candidates study with resources built around the ABIM Medical Oncology examination and assume the content areas line up. They do not. AOBIM publishes its own 17-area outline with its own percentage ranges, and your preparation should be anchored to that document. Domain labels such as "Paraneoplastic syndromes," "Opportunistic infection," and "Cancer trials" appear as discrete content areas in the AOBIM outline, which affects how you should allocate study hours.

The practical advice: use the blueprint above as the organizing spine, and map any outside material onto it. If a resource spends a large share of its pages on a topic that is a 1-5% domain here, down-weight it. If it barely touches a domain that can reach 10% on this exam, supplement it.

Questions about relative difficulty versus other credentials come up often; our guide on how hard the Oncology exam is addresses that directly, and the pass rate page explains what is and is not publicly known.

Mapping the Domains to a Study Schedule

Rather than a generic weekly template, tie your sequencing to the blueprint. A reasonable approach is to put the heaviest domains first so they receive the most repetition, then layer in the mid-weight areas, and finish with the narrow ones plus integrated review.

For a fuller plan, including how to pace review across the exam date, see our Oncology study guide. When you are ready to test retention, original practice questions mapped to the AOBIM outline are available through the main practice test site. A quick-reference review sheet is also available in the Oncology cheat sheet.

Because the exam is 300 questions over seven hours, build stamina as well as knowledge. Practice in long blocks that mix domains, since the real exam will not group questions by organ system. You can also work through additional mixed sets in the practice question bank.

After You Pass: Ten-Year Term and OCC

Certification carries a ten-year term, conditional on Osteopathic Continuous Certification (OCC). For the 2025-2027 cycle, time-limited diplomates need 60 CME credits over three years, including 15 Category 1 and/or Category 1-A credits, along with one quality-improvement activity attestation per three-year cycle and active licensure.

Oncology remains on the remotely proctored subspecialty OCC examination route, offered annually in August. Diplomates may begin that examination two years before certificate expiration, and a successful early renewal extends from the existing certificate's expiration date rather than from the date you pass. Keep this separate from the primary internal-medicine longitudinal assessment; they are distinct components.

Many candidates weigh these ongoing obligations against career benefits. Our analyses of whether the certification is worth it and the salary guide take that on in detail, and the exam dates page covers scheduling and deadlines.

Frequently Asked Questions